and its extractions, tripterygium glycoside and triptolid, have been reported to attenuate proteinuria and podocyte injury in many animal models of kidney diseases by suppression of inflammatory factors (transforming growth factor- β1 [TGF-β1], interleukin-2, and interferon-γ) (Wan et al., 2010), macrophage infiltration (Ma et al., 2013), oxidative stress (lactate dehydrogenase, malondialdehyde [MDA], and super oxide dismutase [SOD]) (Wan et al., 2020). The gene discussed is TGFB1; the disease is kidney disorder.